Showing results (1-10 of 2,862) with videos related to
Sort By:
Pageof 287
Statistics in Medicine|June 8, 2017
BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpointsHeng Zhou, J Jack Lee, Ying YuanJournal of Biopharmaceutical Statistics|November 25, 2024
BOP2-TE: Bayesian optimal phase 2 design for jointly monitoring efficacy and toxicity with application to dose optimizationKai Chen, Heng Zhou, J Jack Lee, et al.Contemporary Clinical Trials|May 5, 2025
Assessing the role of correlation between efficacy and toxicity endpoints in the performance of Bayesian optimal phase II designXun Xu, Ying Yuan, J Jack LeeStatistics in Medicine|October 18, 2019
A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapiesYanhong Zhou, J Jack Lee, Ying YuanClinical Trials (London, England)|May 22, 2014
Adaptive designs for identifying optimal biological dose for molecularly targeted agentsYong Zang, J Jack Lee, Ying YuanClinical Trials (London, England)|January 20, 2024
Statistical and practical considerations in planning and conduct of dose-optimization trialsYing Yuan, Heng Zhou, Suyu LiuClinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2018
Accuracy, Safety, and Reliability of Novel Phase I Trial DesignsHeng Zhou, Ying Yuan, Lei NieJCO Precision Oncology|September 14, 2020
Model-Assisted Designs for Early-Phase Clinical Trials: Simplicity Meets SuperiorityYing Yuan, J Jack Lee, Susan G HilsenbeckPharmaceutical Statistics|June 12, 2020
Bayesian optimal phase II clinical trial design with time-to-event endpointHeng Zhou, Cong Chen, Linda Sun, et al.Statistics in Medicine|April 24, 2018
Comparative review of novel model-assisted designs for phase I clinical trialsHeng Zhou, Thomas A Murray, Haitao Pan, et al.Pageof 287